This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: stub-manual Compound SKIP-FOR-NOW HIGH

Bimatoprost

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Extended Research

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

Editor's verdict SKIP-FOR-NOW HIGH

Works for the cosmetic indication (denser/longer eyelashes, ~25% length / 100% density at 16 weeks per FDA label trial). Off-label scalp use has less data and the cost is higher than minoxidil. For a 20yo with no specific cosmetic eyelash goal and no scalp MPB, no current indication. Flips to OPTIONAL-ADD if (a) Dylan wants cosmetic eyelash density specifically, or (b) MPB onset and adjunct to minoxidil/finasteride/dutasteride considered. Periocular skin pigmentation (darkening of eyelid skin) and iris pigmentation change (irreversible, hazel→brown) are the dominant cosmetic side effects; both rare at correct application but documented.

Research pass: stub-manual
Sourcing deep dive

Rx in US. Latisse brand expensive; generic bimatoprost ophthalmic solutions (intended for glaucoma) sold via overseas pharmacies are functionally equivalent at much lower cost — common community route.

Verdict change log
  • 2026-06-05 — Initial verdict SKIP-FOR-NOW. No current cosmetic eyelash indication for Dylan. (stub)

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…